11/28 Prophylaxis study
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248 (Peer Reviewed)
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Hellwig et al., 11/28/2020, retrospective, multiple countries, Africa, peer-reviewed, 2 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.
risk of COVID-19 case, 78.0% lower, RR 0.22, p < 0.02, African countries.
risk of COVID-19 case, 80.0% lower, RR 0.20, p < 0.001, worldwide.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
